EXACT Sciences (EXAS) Rating Increased to C- at TheStreet

EXACT Sciences (NASDAQ:EXAS) was upgraded by equities research analysts at TheStreet from a “d” rating to a “c-” rating in a research note issued to investors on Tuesday.

EXAS has been the topic of several other reports. UBS Group started coverage on EXACT Sciences in a report on Tuesday, October 9th. They issued a “buy” rating and a $100.00 target price on the stock. Leerink Swann reaffirmed an “outperform” rating and issued a $76.00 target price (up from $67.00) on shares of EXACT Sciences in a report on Wednesday, July 18th. Canaccord Genuity lifted their target price on EXACT Sciences from $72.00 to $87.00 and gave the stock a “buy” rating in a report on Wednesday, September 12th. BTIG Research lifted their target price on EXACT Sciences to $95.00 and gave the stock a “buy” rating in a report on Wednesday, August 22nd. Finally, BidaskClub cut EXACT Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $84.08.

Shares of EXACT Sciences stock traded up $2.38 during trading hours on Tuesday, hitting $77.86. The company’s stock had a trading volume of 798,212 shares, compared to its average volume of 2,173,873. EXACT Sciences has a 12-month low of $37.36 and a 12-month high of $81.22. The company has a market capitalization of $9.12 billion, a price-to-earnings ratio of -78.65 and a beta of 1.21. The company has a quick ratio of 11.72, a current ratio of 12.08 and a debt-to-equity ratio of 0.94.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, October 30th. The medical research company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.05. EXACT Sciences had a negative return on equity of 20.18% and a negative net margin of 35.83%. The business had revenue of $118.29 million for the quarter, compared to the consensus estimate of $109.33 million. During the same period in the previous year, the business earned ($0.23) earnings per share. The business’s revenue was up 63.0% on a year-over-year basis. On average, equities analysts expect that EXACT Sciences will post -1.53 earnings per share for the current year.

In other EXACT Sciences news, Director Michael S. Wyzga sold 2,468 shares of the business’s stock in a transaction that occurred on Tuesday, August 28th. The stock was sold at an average price of $74.85, for a total transaction of $184,729.80. Following the completion of the transaction, the director now owns 9,112 shares in the company, valued at $682,033.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider D Scott Coward sold 2,190 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $79.51, for a total value of $174,126.90. The disclosure for this sale can be found here. Insiders have sold 218,255 shares of company stock worth $15,791,740 over the last three months. 3.20% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the business. Swiss National Bank boosted its position in shares of EXACT Sciences by 0.9% during the third quarter. Swiss National Bank now owns 212,619 shares of the medical research company’s stock valued at $16,780,000 after buying an additional 2,000 shares during the period. MML Investors Services LLC boosted its position in shares of EXACT Sciences by 38.0% during the third quarter. MML Investors Services LLC now owns 5,050 shares of the medical research company’s stock valued at $399,000 after buying an additional 1,391 shares during the period. Dakota Wealth Management purchased a new position in shares of EXACT Sciences during the third quarter valued at approximately $237,000. Biondo Investment Advisors LLC boosted its position in shares of EXACT Sciences by 37.6% during the third quarter. Biondo Investment Advisors LLC now owns 153,710 shares of the medical research company’s stock valued at $12,131,000 after buying an additional 41,965 shares during the period. Finally, Commonwealth Equity Services LLC boosted its position in shares of EXACT Sciences by 11.5% during the third quarter. Commonwealth Equity Services LLC now owns 21,273 shares of the medical research company’s stock valued at $1,678,000 after buying an additional 2,193 shares during the period. Institutional investors and hedge funds own 87.06% of the company’s stock.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: What is the Dow Jones Industrial Average (DJIA)?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply